{
    "organizations": [],
    "uuid": "09b1bed7174c785ff8096c2394e14cdba0afdea8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-krystal-biotechs-kb103-receives-or/brief-krystal-biotechs-kb103-receives-orphan-medicinal-product-designation-in-europe-for-dystrophic-epidermolysis-bullosa-idUSFWN1RW0JA",
    "ord_in_thread": 0,
    "title": "BRIEF-Krystal Biotech’S Kb103 Receives Orphan Medicinal Product Designation In Europe For Dystrophic Epidermolysis Bullosa",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - Krystal Biotech Inc:\n* KRYSTAL BIOTECH’S KB103 RECEIVES ORPHAN MEDICINAL PRODUCT DESIGNATION IN EUROPE FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-19T20:07:00.000+03:00",
    "crawled": "2018-04-20T11:32:05.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "krystal",
        "biotech",
        "inc",
        "krystal",
        "biotech",
        "kb103",
        "receives",
        "orphan",
        "medicinal",
        "product",
        "designation",
        "europe",
        "dystrophic",
        "epidermolysis",
        "bullosa",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}